Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
Authors Miyamoto N, Mandai M, Kojima H, Kameda T, Shimozono M, Nishida A, Kurimoto Y
Received 26 January 2017
Accepted for publication 30 March 2017
Published 28 April 2017 Volume 2017:11 Pages 809—816
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Yang Liu
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Noriko Miyamoto,1,2 Michiko Mandai,1,3 Hiroshi Kojima,1,2 Takanori Kameda,1,2 Masataka Shimozono,1,2 Akihiro Nishida,1,2 Yasuo Kurimoto1,2
1Department of Ophthalmology, Kobe City Medical Center General Hospital, 2Department of Ophthalmology, Institute of Biomedical Research and Innovation, 3Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan
Purpose: To evaluate the response to and dependence on aflibercept or ranibizumab in patients with age-related macular degeneration (AMD).
Methods: We retrospectively reviewed AMD patients who received induction therapy with aflibercept or ranibizumab for the following parameters: whether complete resolution of the retinal fluid (“good response”) was achieved and whether recurrence was observed within 3 months (“dependent”) after the induction treatment. With aflibercept treatment, treatment-naïve eyes with a good response/non-dependence were recommended a pro re nata regimen, and other eyes were recommended a proactive bimonthly regimen, followed by monitoring of visual acuity (VA) for 12 months. The measured values of the groups were compared using one-way analysis of variance with Tukey’s test to evaluate the difference between baseline and postinjection VA.
Results: Among the treatment-naïve eyes, 76% had a good response to aflibercept and 37% of these were aflibercept-dependent, while 58% had a good response to ranibizumab but 51% of these were ranibizumab-dependent. Among the eyes that converted from ranibizumab treatment, 92% of the good responders to ranibizumab with dependence and 76% of the poor responders on ranibizumab had a good response to aflibercept. With aflibercept treatment, the mean VA of treatment-naïve patients was significantly better than the baseline VA over 12 months (P<0.001), and the VA of the converted group improved significantly with proactive treatment and the improvement was continuously maintained from 6 to 12 months.
Conclusion: The evaluation of response to and dependence on anti-vascular endothelial growth factor therapies in AMD was useful and practical in managing therapeutic protocols to obtain a good VA.
Keywords: aflibercept, ranibizumab, recurrence, dependence, visual acuity, proactive treatment
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]